Gilteritinib
Acute Myeloid Leukemia, MLL Gene Rearrangement
Explore 15 assets in Acute Myeloid Leukemia, MLL Gene Rearrangement →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Uma Borate
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06222580CT.gov SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia, MLL Gene Rearrangement
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Gilteritinib (this asset) | Uma Borate | P1 | CC · 43 |
| Cytarabine | National Cancer Institute (NCI) | P2 | B |
| Revumenib | National Cancer Institute (NCI) | P2 | B |
| Hydrocortisone | Children's Oncology Group | P2 | CCC |
| Calaspargase Pegol | Children's Oncology Group | P2 | CCC |
| Prednisolone | Children's Oncology Group | P2 | CCC |
| Vincristine Sulfate | Children's Oncology Group | P2 | CCC |
| Fludarabine | Children's Oncology Group | P2 | CCC |
| Prednisone | Children's Oncology Group | P2 | CCC |
+6 more in the Acute Myeloid Leukemia, MLL Gene Rearrangement cohort
Other indications for Gilteritinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication | — | P3 | BB · 69 |
| Myelodysplastic Syndrome With Excess Blasts-2 | — | P3 | BB · 66 |
| Acute Myeloid Leukemia | — | P3 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Gilteritinib in Acute Myeloid Leukemia, MLL Gene Rearrangement. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/gilteritinib-acute-myeloid-leukemia-mll-gene-rearrangement
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →